Products
AI Benchmark
Desktop
Mobile
Monthly visits
<5K
Oct 2026
Public revenue
Undisclosed
No public revenue evidence yet
Entry price
$5.99/mo
Lower than 93% of peersNiche median $30/mo
Creators
Aayushee Thakor
No social account linked
Launched
8mo ago
2026-04-03 · Est.

Traffic

Last 12 months
Monthly visitsData through Oct 2026
Events1 marketing move

Marketing moves

Launches, search & content, referrals, promotions
  • Launched on Product HuntLaunch

    Validate your startup idea in 10 steps with AI

    Apr 3 · 8mo agoLaunch page

Traffic sources

Oct 2026

Traffic breakdown

Channels

No data yet

Countries

No data yet

Search

Domain authority —Domain registered 2025-08-23

No search keyword data for this website yet.

Traffic data: Vaneform

Pricing

Free Plan
Unknown
15 Tokens · Explore all 10 modules · AI chat across every module
50 Tokens
₹499
50 Tokens · 5 full deep-research runs · All 10 modules unlocked · PDF report generation included

Trial: None · Observed 2026-11-07 · Source page

Entry price $5.99/mo, Lower than 93% of peers; “Fundraising & Cap Tables” median is $30/mo.View pricing benchmark

Pages & changes

Tracked since 2026-04-03

Key pages

Weekly snapshots
Home
bizgyde.ai/ Snapshot 2026-11-07

Changes

No pricing, plan, or positioning changes detected since tracking started.

Questions & evidence

How much does BizGyde cost?
Free Plan: Unknown; 50 Tokens: ₹499. Observed 2026-11-07. Check the source for current billing terms, usage limits and taxes.Source
How much website traffic does BizGyde get?
Vaneform estimates <5K website visits in 2026-10. Visits can include repeat visits; this estimate measures web traffic separately from paying customers or revenue.Source
What is BizGyde and what platforms does it support?
BizGyde is catalogued under Fundraising & Cap Tables: Your AI Venture Mentor.. Supported platforms: Web.

Related products in this category

Finance / Fundraising & Cap Tables

These products share a catalog category. Compare customer tasks, features and deployment requirements before treating them as alternatives.